ANDAORALTABLET
Approved
Jul 2016
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
NILUTAMIDE (nilutamide) by ANI Pharmaceuticals is androgen receptor antagonists [moa]. First approved in 2016.
Drug data last refreshed 20h ago
$0.0BPart D
Mechanism of Action
Androgen Receptor Antagonists
Pharmacologic Class:
Androgen Receptor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Started May 2009
57 enrolled
Prostate Cancer
Company
Worked on NILUTAMIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.